Free Trial
NASDAQ:FTRE

Fortrea (FTRE) Stock Price, News & Analysis

$17.64 -0.67 (-3.66%)
As of 01/14/2025 04:00 PM Eastern

About Fortrea Stock (NASDAQ:FTRE)

Key Stats

Today's Range
$17.00
$18.52
50-Day Range
$17.10
$23.73
52-Week Range
$16.53
$41.02
Volume
977,965 shs
Average Volume
970,239 shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.30
Consensus Rating
Reduce

Company Overview

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Fortrea Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
69th Percentile Overall Score

FTRE MarketRank™: 

Fortrea scored higher than 69% of companies evaluated by MarketBeat, and ranked 461st out of 955 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fortrea has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on no buy ratings, 11 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Fortrea has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Fortrea's stock forecast and price target.
  • Earnings Growth

    Earnings for Fortrea are expected to grow by 147.37% in the coming year, from $0.57 to $1.41 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fortrea is -5.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fortrea is -5.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Fortrea has a PEG Ratio of 3.02. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Fortrea has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.41% of the float of Fortrea has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortrea has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Fortrea has recently increased by 8.33%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Fortrea does not currently pay a dividend.

  • Dividend Growth

    Fortrea does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.41% of the float of Fortrea has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortrea has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Fortrea has recently increased by 8.33%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Fortrea has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Fortrea this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for FTRE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Fortrea to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fortrea insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $203,275.00 in company stock.

  • Percentage Held by Insiders

    Only 0.12% of the stock of Fortrea is held by insiders.

  • Read more about Fortrea's insider trading history.
Receive FTRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortrea and its competitors with MarketBeat's FREE daily newsletter.

FTRE Stock News Headlines

I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
15 Stocks Targeted By Activist Hedge Funds
Fortrea Holdings Inc put volume heavy and directionally bearish
Fortrea: Turning Around As The Activists Move In
See More Headlines

FTRE Stock Analysis - Frequently Asked Questions

Fortrea's stock was trading at $18.65 at the beginning of 2025. Since then, FTRE shares have decreased by 5.4% and is now trading at $17.64.
View the best growth stocks for 2025 here
.

Fortrea Holdings Inc. (NASDAQ:FTRE) announced its quarterly earnings data on Friday, November, 8th. The company reported $0.23 earnings per share for the quarter, missing analysts' consensus estimates of $0.25 by $0.02. Fortrea's revenue was down 5.4% compared to the same quarter last year.

Fortrea's top institutional investors include Nordea Investment Management AB (1.71%) and Salem Investment Counselors Inc. (0.01%). Insiders that own company stock include Thomas Pike and Peter M Neupert.
View institutional ownership trends
.

Shares of FTRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fortrea investors own include AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/08/2024
Today
1/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:FTRE
Fax
N/A
Employees
18,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.30
High Stock Price Target
$27.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+32.1%
Consensus Rating
Reduce
Rating Score (0-4)
1.92
Research Coverage
12 Analysts

Profitability

Net Income
$-3,400,000.00
Pretax Margin
-8.04%

Debt

Sales & Book Value

Annual Sales
$2.98 billion
Cash Flow
$2.19 per share
Book Value
$19.58 per share

Miscellaneous

Free Float
89,592,000
Market Cap
$1.58 billion
Optionable
Optionable
Beta
1.24
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:FTRE) was last updated on 1/15/2025 by MarketBeat.com Staff
From Our Partners